Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Metabolism & Endocrine
Filter     Order     Display # 
Date Item Title
28 Aug 2007 Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
24 Aug 2007 Teijin and Chugai enter an agreement to co-develop Ipsen's anti-diabetic medicine in Japan
24 Aug 2007 AtheroGenics Announces First Patients Enrolled in ANDES Phase III Diabetes Clinical Trial
22 Aug 2007 Sirtris Pharmaceuticals initiates Phase 2a clinical trial in patients with Type 2 diabetes
21 Aug 2007 Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA
21 Aug 2007 Solvay Pharmaceuticals, Inc. Receives Approvable Letter from FDA with Respect to New Drug Application for CREON(R)
21 Aug 2007 Metabasis Therapeutics Presents Preclinical Results Demonstrating Potential Advantages of MB07811 as a Treatment for Hyperlipidemia
21 Aug 2007 Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients
20 Aug 2007 IsoTis receives FDA clearance for Accell Family of Products
19 Aug 2007 Reclast(R) receives US regulatory approval as first and only once-yearly treatment for women with postmenopausal osteoporosis
15 Aug 2007 Altus Pharmaceuticals’ ALTU-237 Enters Phase I Clinical Trial for the Treatment of Hyperoxalurias and the Potential Prevention of Kidney Stone Formation
15 Aug 2007 Oramed Pharmaceuticals Successfully Completes Phase 1A Trials
15 Aug 2007 CombinatoRx announces initiation of phase 2a proof-of-concept clinical study with CRx-401 for Type 2 diabetes
15 Aug 2007 GlaxoSmithKline updates prescribing information for Avandia in the US
13 Aug 2007 BioMarin partner AnGes MG, Inc. submits BLA to Japanese Ministry of Health
13 Aug 2007 BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07
12 Aug 2007 LifeCycle Pharma and Sciele Pharma announce FDA approval of new formulation of Fenofibrate in 120 mg. and 40 mg. dosage strengths
10 Aug 2007 Tissera reports significant milestone achievement in its large animal diabetic model studies.
10 Aug 2007 Georgetown University and Samaritan sign exclusive licensing agreement for novel treatment of Cushing's syndrome
10 Aug 2007 Sirtris Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of SRT501 in MELAS
09 Aug 2007 Positive Phase 1b transdermal insulin clincial trial results
09 Aug 2007 Tercica Receives Marketing Approval for Increlex in the European Union
08 Aug 2007 MicroDose announces positive results from the QDose inhaled insulin glucose clamp study
08 Aug 2007 KineMed and Merck Enter Collaboration in Atherosclerosis
04 Aug 2007 Macrogenics Begins Global Phase 2/3 Protege Study In Recent-onset Type 1 Diabetes Mellitus
03 Aug 2007 Rheoscience and Dr. Reddy’s commence the first Phase III trial of Balaglitazone (DRF 2593)
03 Aug 2007 Unigene Initiates Oral Calcitonin Clinical Study in Humans
02 Aug 2007 Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
01 Aug 2007 Laureate Pharma Announces Agreement with Enobia Pharma, Inc.
01 Aug 2007 Ajinomoto and Takeda submits Additional Indication for Paget's Disease of Bone for Risedronate Sodium Hydrate designated as Orphan Drug
31 Jul 2007 GlaxoSmithKline presents Avandia data to FDA
31 Jul 2007 Quigley Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients
27 Jul 2007 Genaera Corporation Presents New Preclinical Data For Obesity Compound Trodusquemine (msi-1436) At Cbi Conference
26 Jul 2007 Resverlogix Announces a Second Proof-of-Concept Milestone
26 Jul 2007 Athersys Begins Phase I Trial for ATHX-105 for Treatment of Obesity
26 Jul 2007 Kuvan Receives Priority Review Status from FDA
25 Jul 2007 OREXIGEN(TM) Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of EMPATIC(TM) to Treat Obesity
20 Jul 2007 Metabolex announces full enrollment of phase 2/3 study of MBX-102/JNJ 39659100 in patients with Type 2 diabetes
20 Jul 2007 Galvus(R), a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval
20 Jul 2007 Aclasta(R) recommended for European approval as the first once-yearly treatment for women with postmenopausal osteoporosis
20 Jul 2007 Tercica Completes Enrollment of Clinical Trial MS301 Evaluating Treatment with Increlex in Children with Primary IGFD
20 Jul 2007 HMP approves labelling update of Acomplia(R) in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depression
19 Jul 2007 Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
19 Jul 2007 Merck Transfers Abbott Rights for Niaspan Outside the U.S.
18 Jul 2007 Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir
18 Jul 2007 Ambrilia Completes Korean Licensing Partnership with Shin Poong for its Long-Acting Formulation of Octreotide
18 Jul 2007 CVBT Announces Positive Pre-Clinical Results for Protein-Based Drug Candidate to Treat Osteoporosis
18 Jul 2007 Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit
18 Jul 2007 PPD Completes First-in-Human Trial for Novel Statin
17 Jul 2007 XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 451 - 500 of 1041

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics